Human Bioequivalence Study of Clarithromycin from Two Tablet Formulations after Single Oral Administration

2001 ◽  
Vol 21 (3) ◽  
pp. 211-217 ◽  
Author(s):  
Ioannis Niopas ◽  
Athanasios C. Daftsios ◽  
Nicolaos Nikolaidis
Keyword(s):  
Oral Administration ◽  
Bioequivalence Study ◽  
Single Oral Administration ◽  
Tablet Formulations

Bioequivalence of Two Tablet Formulations of Atenolol after Single Oral Administration in Healthy Volunteers

2011 ◽  
Vol 50 (03) ◽  
pp. 243-247
Author(s):  
Ioannis Niopas ◽  
Athanasios Daftsios ◽  
Ioannis Xanthakis ◽  
Nicolaos Nikolaidis ◽  
Samuel Njau
Keyword(s):  
Oral Administration ◽  
Healthy Volunteers ◽  
Single Oral Administration ◽  
Tablet Formulations

Evaluation of the Bio equivalence and Pharmacokinetics of Two Lisinopril Tablet Formulations after Single Oral Administration in Healthy Volunteers

2011 ◽  
Vol 54 (01) ◽  
pp. 15-19
Author(s):  
Manolis Georgarakis ◽  
Andreas Tsakalof ◽  
Fotini Zougrou ◽  
Georgios Kontopoulos ◽  
Iakovos Tsiptsios
Keyword(s):  
Oral Administration ◽  
Healthy Volunteers ◽  
Single Oral Administration ◽  
Tablet Formulations

scholarly journals Bioequivalence study of two oral lincomycin formulations (lincopharm 800® and lincoyosr®) in broiler chickens

2020 ◽  
Vol 8 (1) ◽  
pp. 60
Author(s):  
Ashraf Elkomy ◽  
Mohamed Aboubakr
Keyword(s):  
Oral Administration ◽  
Blood Concentration ◽  
Broiler Chickens ◽  
Broiler Chicken ◽  
Bioequivalence Study ◽  
Wing Vein ◽  
Blood Samples ◽  
Single Oral Administration ◽  
Acceptance Range ◽  
Kinetics Of

The present study was designed to assess the comparative bio-equivalence of Lincopharm 800® and Lincoyosr® in healthy broiler chicken after oral administration of both products in a dose of 20 mg lincomycin base/kg b.wt. Twenty four broiler chickens were divided into two groups. The first group was designed to study the pharmacokinetics of Lincopharm 800®, while the 2nd group was designed to study the pharmacokinetics of Lincoyosr®. Each broiler chicken in both groups was orally administered with 20 mg lincomycin base/kg b.wt. Blood samples were obtained from the wing vein and collected immediately before and at 0.08, 0.16, 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours after a single oral administration. The disposition kinetics of Lincopharm 800® and Lincoyosr® following oral administration of 20 mg lincomycin base /kg b.wt, revealed that the maximum blood concentration of lincomycin [Cmax] were 4.81 and 4.62 μg/ml and attained at [tmax] of 1.36 and 1.35 hours, respectively. In conclusion: Lincoyosr® is bioequivalent to Lincopharm 800® since the ratios of Cmax, AUC0-24 and AUC0-∞ (T/R) was 0.96, 0.92 and 0.91 respectively. These are within the bioequivalence acceptance range. Lincoyosr® and Lincopharm 800® are therefore bioequivalent and interchangeable.   

Sign in / Sign up

Export Citation Format

Share Document